Treatment with a novel hypoxia-inducible factor hydroxylase inhibitor (TRC160334) ameliorates ischemic acute kidney injury

P Jamadarkhana, A Chaudhary, L Chhipa… - American journal of …, 2012 - karger.com
P Jamadarkhana, A Chaudhary, L Chhipa, A Dubey, A Mohanan, R Gupta, S Deshpande
American journal of nephrology, 2012karger.com
Background: Hypoxia-inducible factor (HIF) transcriptional system plays a central role in
cellular adaptation to low oxygen levels. Preconditional activation of HIF and/or expression
of its individual target gene products leading to cytoprotection have been well established in
hypoxic/ischemic renal injury. Increasing evidence indicate HIF activation is involved in
hypoxic/ischemic postconditioning of heart, brain and kidney. Very few studies evaluated the
potential benefits of postischemia HIF activation in renal injury employing a pharmacological …
Abstract
Background: Hypoxia-inducible factor (HIF) transcriptional system plays a central role in cellular adaptation to low oxygen levels. Preconditional activation of HIF and/or expression of its individual target gene products leading to cytoprotection have been well established in hypoxic/ischemic renal injury. Increasing evidence indicate HIF activation is involved in hypoxic/ischemic postconditioning of heart, brain and kidney. Very few studies evaluated the potential benefits of postischemia HIF activation in renal injury employing a pharmacological agent. We hypothesized that postischemia augmentation of HIF activation with a pharmacological agent would protect renal ischemia/reperfusion injury. For this, TRC160334, a novel HIF hydroxylase inhibitor, was used. Methods: TRC160334, a novel HIF hydroxylase inhibitor, was synthesized. Ability of TRC160334 for stabilization of HIF-α and consequent HIF activation was evaluated in Hep3B cells. Efficacy of TRC160334 was evaluated in a rat model of ischemia/reperfusion-induced AKI. Two different treatment protocols were employed, one involved treatment with TRC160334 before onset of ischemia, the other involved treatment after the reperfusion of kidneys. Results: TRC160334 treatment results in stabilization of HIF-α leading to HIF activation in Hep3B cells. Significant reduction in renal injury was observed by both treatment protocols and remarkable reduction in serum creatinine (23 and 71% at 24 and 48 h, respectively, p < 0.01) was observed with TRC160334 treatment applied after reperfusion. Urine output was significantly improved up to 24 h by both treatment protocols. Conclusion: The data presented here provide pharmacologic evidence for postischemia augmentation of HIF activation by TRC160334 as a promising and clinically feasible strategy for the treatment of renal ischemia/reperfusion injury.
Karger